Collectively, our work can draw the following conclusions: elevated AIM2 levels in RCC promotes FOXO3a phosphorylation and proteasome degradation, thereby reducing its transcriptional effect on ACSL4; and reduced ACSL4 levels suppress ferroptosis, thereby promoting RCC progression and sunitinib resistance. The gene discussed is ACSL4; the disease is renal cell carcinoma.